Outlook Therapeutics, Inc. (OTLK) News
Track canonical SquawkNews coverage tagged to OTLK, Outlook Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 19 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Access the segment hereISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. NASDAQ:OTLK, a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg,
REGULATION | Sep 10, 2026, 01:11 PM UTC
L
Outlook Therapeutics appoints Kevin Lundquist as CFO
Outlook Therapeutics appointed Kevin Lundquist as chief financial officer as it prepares for a U.S. commercial launch of LYTENAVA.
EQUITY | Aug 27, 2026, 08:07 PM UTC
L
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
EQUITY | Aug 27, 2026, 01:08 PM UTC
L
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
EQUITY | Aug 27, 2026, 01:01 PM UTC
H
Analysts update targets on AMAT, OTLK, PLXS, AIT, CCOI
Wall Street analysts maintained or adjusted ratings and price targets on Applied Materials, Outlook Therapeutics, Plexus, Applied Industrial Technologies and Cogent Communications after each company’s recent results or g
EARNINGS | Aug 17, 2026, 10:59 AM UTC
L
Outlook Therapeutics reports Q3 2026 results, says FDA approved Lytenava
Outlook Therapeutics said it released third-quarter fiscal 2026 results and hosted a call, while management highlighted FDA approval of Lytenava for wet AMD in the U.S.
EARNINGS | Aug 14, 2026, 01:25 PM UTC
M
Premarket selling hits CLBT, OTLK, STUB, ABEO, CBRS
CLBT, OTLK, STUB, ABEO and CBRS are indicated lower in premarket trading, with no catalyst or additional details supplied in the alert.
EQUITY | Aug 13, 2026, 11:55 AM UTC
L
Multiple companies announce shelf filings and equity, debt offerings
The wire lists several capital-raising actions, including ARE pricing $1,000,000,000 of Series A fixed-to-fixed reset rate junior subordinated notes due 2057 and RHP closing a common stock offering with full over-allotme
MNA | Aug 13, 2026, 10:31 AM UTC
H
OTLK prices $55M share offering at $0.99
OTLK priced a $55M offering at $0.99 per share, according to TradeXchange Newsdesk.
EQUITY | Aug 13, 2026, 10:00 AM UTC
M
OTLK Falls After Hours
OTLK is falling after hours with no magnitude or catalyst supplied
EQUITY | Aug 12, 2026, 08:01 PM UTC
L
Outlook Therapeutics Director Buys 95,398 Shares
Director buys 95,398 shares at $1.048
FX | Jul 29, 2026, 07:20 PM UTC
L
Outlook Therapeutics price target raised by $1.10 at H.C. Wainwright, here's why
Outlook Therapeutics price target raised by $1.10 at H.C. Wainwright, here's why
EQUITY | Jul 27, 2026, 04:08 PM UTC
L
OTLK upgraded from Neutral to Buy W/ $4 PT @ BTIG
OTLK upgraded from Neutral to Buy W/ $4 PT @ BTIG
EQUITY | Jul 27, 2026, 12:47 PM UTC
L
OTLK Upgrade from Neutral to Buy W/$4.00 PT at BTIG
OTLK Upgrade from Neutral to Buy W/$4.00 PT at BTIG
EQUITY | Jul 27, 2026, 12:07 PM UTC
L
OTLK resumes trading after halt, now down -9%
OTLK resumes trading after halt, now down -9%
EQUITY | Jul 24, 2026, 07:06 PM UTC
L
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGN seeing little to no movement post OTLK jumping 24% on FDA approval of Lytenava for wet AMD thus far
REGULATION | Jul 24, 2026, 06:52 PM UTC
L
OTLK outlook Therapeutics - lytenava expected to be available to U.S. patients before year-end
OTLK outlook Therapeutics - lytenava expected to be available to U.S. patients before year-end
EQUITY | Jul 24, 2026, 06:40 PM UTC
L
OTLK outlook Therapeutics announces lytenava™ FDA approval as the first and only FDA-approved ophthalmic bevacizumab for the treatment of we
OTLK outlook Therapeutics announces lytenava™ FDA approval as the first and only FDA-approved ophthalmic bevacizumab for the treatment of wet amd Outlook Therapeutics - lytenava anticipated to have 12 years of market exc
REGULATION | Jul 24, 2026, 06:40 PM UTC
L
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for
ELVT SNY OTSKY MNKD OTLK VTRS Here are the key confirmed or reported upcoming PDUFA (Prescription Drug User Fee Act) target action dates for remainder of month: --ELVT expected around 7/23 – Drug rivoceranib + camrelizum
EQUITY | Jul 20, 2026, 05:31 PM UTC